Want to see AU:IDT full AI Analyst Report?
IDT Australia Limited (IDT) AI Stock Analysis
IDT Australia Limited
(ASX:IDT)
The score is held back primarily by weak financial performance: despite a revenue rebound and improved cash generation, the company remains loss-making with slightly negative free cash flow and higher leverage than prior years. Technicals are also soft with negative MACD and a low RSI, while valuation is constrained by a negative P/E and no dividend yield data.
IDT Australia Limited (IDT) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 19.27M
- Dividend Yield
- ―
- Average Volume (3M)
- 212.18K
- Price to Earnings (P/E)
- -6.9
- Beta (1Y)
- 1.59
- Revenue Growth
- 5.93%
- EPS Growth
- 66.32%
- Country
- Australia
- Employees
- 156
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
IDT Australia Limited Business Overview & Revenue Model
Company Description
IDT Australia Limited is an enterprise deeply involved in the entire lifecycle of pharmaceutical products, from initial research and development through to manufacturing and global distribution of both active pharmaceutical ingredients (APIs) and fin...
How the Company Makes Money
IDT primarily makes money by providing contract services to pharmaceutical and healthcare companies, earning revenue from fees charged for manufacturing and related services delivered under customer contracts. Key revenue streams typically include (w...
IDT Australia Limited Financial Statement Overview
Summary
Revenue has rebounded strongly from the 2023 trough and operating cash flow turned positive in 2026, signaling an early-stage turnaround. However, profitability remains a key weakness (2026 net margin -13.35%, EBIT margin -8.09%), free cash flow is still slightly negative (A$-0.24m), and leverage has increased (debt-to-equity ~0.57), keeping execution risk elevated.
Income Statement
28NegativeBalance Sheet
56NeutralCash Flow
34Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.36M | 20.36M | 19.77M | 13.23M | 6.93M | 12.11M |
| Gross Profit | 4.29M | 4.29M | 9.69M | 10.42M | -3.53M | 2.82M |
| EBITDA | -743.00K | -743.00K | -6.54M | -5.56M | -8.83M | -340.00K |
| Net Income | -2.72M | -2.72M | -8.06M | -5.41M | -8.50M | -1.16M |
Balance Sheet | ||||||
| Total Assets | 34.89M | 34.89M | 36.92M | 31.37M | 28.29M | 30.08M |
| Cash, Cash Equivalents and Short-Term Investments | 2.52M | 2.52M | 4.11M | 904.00K | 4.43M | 9.21M |
| Total Debt | 10.82M | 10.82M | 10.40M | 4.47M | 740.00K | 881.00K |
| Total Liabilities | 15.85M | 15.85M | 15.03M | 7.93M | 4.15M | 3.46M |
| Stockholders Equity | 19.04M | 19.04M | 21.89M | 23.44M | 24.14M | 26.63M |
Cash Flow | ||||||
| Free Cash Flow | -243.00K | -243.00K | -7.55M | -10.30M | -8.42M | 1.95M |
| Operating Cash Flow | 1.07M | 1.07M | -6.25M | -9.60M | -7.90M | 2.86M |
| Investing Cash Flow | 2.19M | 2.19M | -4.50M | -1.09M | -522.00K | -912.00K |
| Financing Cash Flow | -1.25M | -1.25M | 10.75M | 6.77M | 3.64M | 337.00K |
IDT Australia Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDT, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 46.20 is Neutral, neither overbought nor oversold. The STOCH value of 53.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IDT.
IDT Australia Limited Peers Comparison
Overall Rating
AU:VLS82Outperform
AU:MVP67Neutral
AU:CAN53Neutral
AU:LGP45Neutral- AU:IDT44Neutral
AU:PKP39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:VLS | 82Outperform | AUD 147.70M | 13.70 | 19.91% | 5.29% | 12.19% | 22.36% |
| AU:MVP | 67Neutral | AUD 41.12M | 65.18 | 1.13% | ― | 8.99% | 450.00% |
| AU:CAN | 53Neutral | AUD 8.30M | 0.30 | 64.70% | ― | -24.22% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:LGP | 45Neutral | AUD 49.68M | -13.04 | -1.67% | ― | 15.21% | -141.82% |
| AU:IDT | 44Neutral | AUD 18.20M | -6.88 | -13.81% | ― | 5.93% | 66.32% |
| AU:PKP | 39Underperform | AUD 21.43M | -5.07 | 4388.00% | ― | -19.73% | 50.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:IDT | IDT Australia Limited | 0.04 | -0.02 | -26.67% | |
| AU:CAN | Cann Group Ltd. | 0.01 | -0.00 | -9.09% | |
| AU:VLS | Vita Life Sciences Limited | 2.74 | 0.47 | 20.76% | |
| AU:LGP | Little Green Pharma Ltd. | 0.06 | -0.07 | -53.85% | |
| AU:MVP | Medical Developments International Limited | 0.36 | -0.32 | -46.32% | |
| AU:PKP | Althea Group Holdings Ltd. | 0.02 | -0.01 | -23.81% |
IDT Australia Limited Corporate Events
IDT Australia Plans Issue of 6 Million Options to Bolster Capital Flexibility
IDT Australia Limited has notified the ASX of a proposed issue of up to 6 million options, each expiring on various dates and with differing exercise prices, under a placement or similar type of securities issue. The options are scheduled for issue o...
IDT Australia Issues 14.3 Million Unquoted Performance Rights Under Incentive Scheme
IDT Australia Limited has notified the market of the issue of 14,300,000 unquoted performance rights under its employee incentive scheme, effective October 23, 2026. The new rights, which are not intended to be quoted on the ASX, signal the company&#...
IDT Australia Issues New Shares Under Employee Performance Rights Plan
IDT Australia Limited has issued 1,388,545 fully paid ordinary shares to employees following the exercise of performance rights under its Employee Performance Rights Plan. The issue, completed on 2 October 2026, reflects ongoing use of equity-based i...
IDT Australia Expands Listed Capital with New Share Quotation
IDT Australia Limited has applied for quotation of 1,388,545 new ordinary fully paid shares on the ASX, with the securities issued on 02 October 2026. The application reflects an increase in the company’s listed capital base, which may support...
IDT Australia Issues 2.7 Million Unquoted Performance Rights
IDT Australia Limited has notified the market of the issue of 2,711,096 unquoted performance rights under its employee incentive scheme.The performance rights, which are not intended to be quoted on the ASX, were issued on 28 August 2026 and reflect...
IDT Australia Seeks ASX Quotation for Employee Incentive Share Issue
IDT Australia Limited has applied for ASX quotation of 1,166,655 fully paid ordinary shares issued to employees as a short‑term incentive at nil consideration. The shares, allotted on August 28, 2026 under the company’s LR7.1 placement ca...
IDT Australia moves to reassure investors after delayed director share notice
IDT Australia Limited has disclosed a change in director Geoffrey Sam’s shareholding, filing an updated notice with the ASX to reflect an equity transaction that occurred on 12 May 2026. The company attributed the delay in lodging the notice to...
IDT Australia Outlines FY26 Results and Investment Risk Framework
IDT Australia Limited has released its full‑year FY26 results presentation, framed around its strategy of advanced manufacturing for breakthrough medicines. The document serves as a high‑level overview of the company’s operations an...
IDT Australia Narrows Losses and Invests to Capture CDMO Growth
IDT Australia has reported a sharp improvement in its fiscal 2026 performance as a strategic reset lifts earnings and reshapes its revenue mix. EBITDA loss narrowed by 85% to $0.9 million, while revenue from its three core verticals – APIs, spe...
IDT Australia Narrows Annual Loss as Revenue Edges Higher
IDT Australia Limited reported a 3.4% increase in revenues and other income to $20.53 million for the year ended 30 June 2026, while significantly narrowing its after-tax loss to $2.72 million from $8.06 million a year earlier. The company did not de...
IDT Australia Director’s Options Expire, Shareholding Unchanged
IDT Australia Limited has disclosed a change in director Mark Simari’s interests, with 6,000,000 unlisted options previously held indirectly through associated entities expiring without consideration. Following this change, Simari’s indir...
IDT Australia Director’s Options Expire, Shareholdings Unchanged
IDT Australia Limited has disclosed a change in the interests of director Geoffrey Sam following the expiry of unlisted options held indirectly through family-related entities. Sam’s indirect holding of 3,000,000 unlisted options has lapsed wit...
IDT Australia Options Lapse, Simplifying Capital Structure
IDT Australia Limited has confirmed the lapse of 12,000,000 listed options, which expired unexercised on 7 August 2026, resulting in the cessation of these securities. The expiry slightly simplifies the company’s capital structure, with no imme...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026